The federal Food and Drug Administration (FDA) announced Friday that it has granted priority review vouchers to three psychedelic drugs being developed to treat certain mental health conditions, Associated Press reports.
The drugs include two psilocybin-based drugs made to treat depression and a psychedelic made using methylone, a substance similar to MDMA, which is designed to treat post-traumatic stress disorder (PTSD). They are not guaranteed to get approved with coupons, but the review period for the drugs should be shortened.
“We owe it to our nation’s veterans and all Americans suffering from these conditions to evaluate these potential therapies as a matter of urgency.” – FDA Commissioner Marty Makary in a statement
The FDA has also approved initial testing for an ibogaine-based drug, DemeRx, as a treatment for alcohol use disorder, the report said.
The announcement comes about a week after President Donald Trump (R) signed an executive order runs the FDA to expedite the review of psychedelics, including psilocybin and ibogaine, as potential mental health treatments.
Currently, all psychedelics are Schedule I under the Controlled Substances Act, reserved for drugs with a “high potential for abuse” and “no currently accepted medical use” in the US.
